Printer Friendly

SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS

    SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
    WALTHAM, Mass., March 5 /PRNewswire/ -- Summit Technology, Inc. (NASDAQ: BEAM) announced that the FDA, after reviewing the data from Summit's Phase I clinical trials, has granted the company approval to begin the second phase of its U.S. human clinical trials using the company's holmium solid state laser for the treatment of hyperopia (farsightedness).
    This second phase will involve the treatment of additional patients at an increased number of clinical sites.  There will be a total of seven sites where FDA clinical trials will be conducted using Summit's OmniMed(tm) holmium laser system.  Summit believes it is the only company currently conducting FDA approved clinical trials for laser refractive surgery with a solid state laser.
    Summit has combined its advanced excimer laser with its holmium laser system to form the first fully integrated ophthalmic workstation for use in refractive surgery.  Summit believes it is the only company using both excimer and holmium laser systems for the treatment of refractive disorders.
    Summit Technology, Inc. has established the leadership position in designing, manufacturing and marketing ophthalmic refractive laser systems.  A major focus of the company's business is in ophthalmology where applications have been developed for the treatment of common vision disorders such as nearsightedness, farsightedness, astigmatism, glaucoma and certain corneal irregularities due to disease or injury. There are believed to be approximately 140 million people in the United States with refractive disorders.  To date, over 10,000 patients have been treated worldwide by ophthalmologists using Summit's laser systems.
    -0-                           3/5/92 R
    /CONTACT:  Paula Rainville of Summit Technology, 617-890-1234/
    (BEAM) CO:  Summit Technology, Inc. ST:  Massachusetts IN:  MTC HEA SU: SH-DD -- NE004 -- 5272 03/05/92 08:40 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 5, 1992
Words:299
Previous Article:PIC 'N' SAVE RELEASES FEBRUARY SALES
Next Article:DEB SHOPS REPORTS SALES AND NET INCOME FOR FISCAL YEAR AND FOURTH QUARTER
Topics:


Related Articles
SUMMIT TECHNOLOGY COMPLETES CLINICAL REQUIREMENTS FOR FDA PHASE III PHOTOREFRACTIVE KERATECTOMY (PRK) U.S. CLINICAL TRIALS
SUMMIT TECHNOLOGY RECEIVES IDE FROM FDA FOR TREATMENT OF ASTIGMATISM WITH HOLMIUM LASER SYSTEM
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
HAHNEMANN OPHTHALMOLOGIST TESTING NEW LASER EYE SURGERY TECHNIQUE
SUMMIT RECEIVES FDA CLEARANCE TO SELL OMNIMED HOLMIUM LASER SYSTEM IN THE UNITED STATES
SUMMIT TECHNOLOGY RECEIVES TWO FDA APPROVALS TO BEGIN PHASE III CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS & ASTIGMATISM
SUMMIT RECEIVES AUTHORIZATION TO CONDUCT NEW CLINICAL TRIAL
Summit Receives FDA Approval to Expand Farsightedness Clinical Trials with Apex Plus Laser
Eclipse Receives Approval to Start The First U.S. Clinical Trials of A New Minimally Invasive Surgical Approach to TMR
Eclipse Submits PMA Application to FDA for Transmyocardial Revascularization

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters